

North America Generic Drugs Market Size and Forecast (2021 - 2031) Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Molecule Type (Antidepressants, Antihistamines, Analgesics, Antibiotics, Antivirals, Diuretics, and Other Molecule Types), Indication (Metabolic Diseases, Cancer, Immunology, Respiratory Disorder, Cardiovascular Disorder, Neurology Disorder, Rare Diseases, and Other Indications), Type (Prescription and OTC Drugs), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

<https://marketpublishers.com/r/N1E3DEF36A00EN.html>

Date: October 2025

Pages: 200

Price: US\$ 3,450.00 (Single User License)

ID: N1E3DEF36A00EN

Abstracts

The North America generic drugs market is projected to grow significantly, reaching approximately USD 289.26 billion by 2031, up from USD 207.73 billion in 2024. This growth represents a compound annual growth rate (CAGR) of 4.9% from 2025 to 2031.

Executive Summary and Market Analysis

The generic drugs sector in North America is witnessing steady expansion, primarily driven by escalating healthcare costs, an increasing population, the expiration of patents for branded medications, and a rising demand for affordable treatment options. The United States, Canada, and Mexico are the primary contributors to this market, with the U.S. holding the largest share. By 2030, it is estimated that one in five Americans

will be over the age of 65, which will heighten the demand for cost-effective treatments for chronic conditions such as diabetes, hypertension, and arthritis.

Government support and regulatory frameworks are also bolstering the market. Agencies like the U.S. Food and Drug Administration (FDA) have implemented accelerated approval pathways for generic drugs, facilitating quicker access to these medications without compromising safety or efficacy. This regulatory environment has made it easier for manufacturers to introduce generics into the market. Additionally, there is a strong focus on healthcare cost containment, with payers and policymakers advocating for the use of generics to lower overall healthcare spending. According to the Association for Accessible Medicines, generics accounted for 90% of prescriptions dispensed in the U.S. and 18% of total drug spending in 2023. The market is also characterized by increased competition and consolidation, as companies expand their portfolios through partnerships and acquisitions to meet the growing demand.

Market Segmentation Analysis

The North America generic drugs market can be segmented based on molecule type, indication, type, and distribution channel:

Molecule Type: The market is divided into several categories, including antidepressants, antihistamines, analgesics, antibiotics, antivirals, diuretics, and others. In 2024, the antibiotics segment held the largest market share.

Indication: The market is segmented into various indications such as metabolic diseases, cancer, immunology, respiratory disorders, cardiovascular disorders, neurology disorders, rare diseases, and others. The cancer segment was the largest in 2024.

Type: The market is further bifurcated into prescription and over-the-counter (OTC) drugs, with the prescription segment holding a larger share in 2024.

Distribution Channel: The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies leading in market share in 2024.

Market Outlook

Biosimilars are becoming increasingly important in the global generic drugs market, driven by several key trends. The expiration of patents for major biologic drugs has opened the door for biosimilars, which provide more affordable alternatives and help reduce healthcare costs. Regulatory bodies like the FDA and the European Medicines Agency (EMA) have established streamlined approval processes for biosimilars, facilitating their timely entry into the market. This has led to greater acceptance among healthcare providers, supported by real-world evidence and successful clinical trials that demonstrate their safety and efficacy. As more biologic patents expire, competition in the market is intensifying, prompting pharmaceutical companies to invest in biosimilar development. Furthermore, biosimilars are gaining traction in emerging markets, improving access to essential biologic treatments at lower costs.

The World Health Organization (WHO) has highlighted that noncommunicable diseases (NCDs) such as cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes are the leading causes of death and disability globally. In 2019, NCDs accounted for 41 million of the 55 million global deaths, representing 75% of all deaths that year. The burden of NCDs is expected to rise, with projections suggesting that by 2050, chronic diseases will account for 86% of the 90 million deaths annually, marking a 90% increase since 2019. This growing prevalence of chronic diseases underscores the urgent need for effective prevention and management strategies. Biosimilars play a crucial role by offering cost-effective treatment options, thereby enhancing access to necessary therapies and alleviating financial burdens on healthcare systems and patients.

Country Insights

The North America generic drugs market is comprised of the U.S., Canada, and Mexico, with the U.S. holding the largest market share in 2024. The U.S. generic drugs market is experiencing robust growth, driven by the increasing burden of chronic illnesses, cancer, and infectious diseases, alongside a push for affordable healthcare solutions. In 2024, approximately 2 million new cancer cases were diagnosed, highlighting the urgent need for cost-effective treatments. While innovative therapies such as therapeutic cancer vaccines and mRNA vaccines show promise, the affordability and accessibility provided by generic drugs remain essential for public health.

The U.S. biopharmaceutical industry, which includes generic manufacturers, is a global leader in innovation and scale, generating over USD 800 billion in direct output in 2022. The industry invested USD 141 billion in domestic research and development, representing a significant portion of U.S. industry-funded medical research.

Company Profiles

Key players in the North America generic drugs market include Teva Pharmaceutical Industries Ltd, Viatris Inc, Dr. Reddy's Laboratories Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, AbbVie Inc, AstraZeneca Plc, Sanofi SA, Aurobindo Pharma Ltd, and Glenmark Pharmaceuticals Ltd. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and meet consumer demands.

Contents

1. INTRODUCTION

- 1.1 Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights

3. RESEARCH METHODOLOGY

- 3.1 Secondary Research
- 3.2 Primary Research
 - 3.2.1 Hypothesis formulation:
 - 3.2.2 Macro-economic factor analysis:
 - 3.2.3 Developing base number:
 - 3.2.4 Data Triangulation:
 - 3.2.5 Country level data:

4. NORTH AMERICA GENERIC DRUGS MARKET LANDSCAPE

- 4.1 Overview
- 4.2 PEST Analysis
- 4.3 Regulatory Landscape
 - 4.3.1 North America
 - 4.3.1.1 United States
 - 4.3.1.2 Canada
 - 4.3.1.3 Mexico
- 4.4 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:
- 4.5 Average Selling Price, 2024
- 4.6 Pipeline Analysis:

5. NORTH AMERICA GENERIC DRUGS MARKET – KEY MARKET DYNAMICS

- 5.1 North America Generic Drugs Market – Key Market Dynamics
- 5.2 Market Drivers

- 5.2.1 Patent Expiry and Loss of Market Exclusivity:
- 5.2.2 Government Policies and Regulatory Support for Generics
- 5.3 Market Restraints
 - 5.3.1 Intense Price Competition and Thin Profit Margins
- 5.4 Market Opportunities
 - 5.4.1 Increasing Government Initiatives to promote the use of generic drugs
- 5.5 Future Trends
 - 5.5.1 Rising Popularity of Biosimilars in the Global Generic Drugs Market
- 5.6 Impact of Drivers and Restraints:

6. GENERIC DRUGS MARKET – NORTH AMERICA ANALYSIS

- 6.1 North America Generic Drugs Market Revenue (US\$ Billion), 2021–2031
- 6.2 North America Generic Drugs Market Forecast Analysis

7. NORTH AMERICA GENERIC DRUGS MARKET ANALYSIS – BY MOLECULE TYPE

- 7.1 Antidepressants
 - 7.1.1 Overview
 - 7.1.2 Antidepressants: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)
- 7.2 Antihistamines
 - 7.2.1 Overview
 - 7.2.2 Antihistamines: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)
- 7.3 Analgesics
 - 7.3.1 Overview
 - 7.3.2 Analgesics: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)
- 7.4 Antibiotics
 - 7.4.1 Overview
 - 7.4.2 Antibiotics: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)
- 7.5 Antivirals
 - 7.5.1 Overview
 - 7.5.2 Antivirals: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)
- 7.6 Diuretics

7.6.1 Overview

7.6.2 Diuretics: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

7.7 Others

7.7.1 Overview

7.7.2 Others: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8. NORTH AMERICA GENERIC DRUGS MARKET ANALYSIS – BY INDICATION

8.1 Metabolic Diseases

8.1.1 Overview

8.1.2 Metabolic Diseases: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.2 Cancer

8.2.1 Overview

8.2.2 Cancer: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.3 Immunology

8.3.1 Overview

8.3.2 Immunology: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.4 Respiratory Disorder

8.4.1 Overview

8.4.2 Respiratory Disorder: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.5 Cardiovascular Disorder

8.5.1 Overview

8.5.2 Cardiovascular Disorder: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.6 Neurology Disorder

8.6.1 Overview

8.6.2 Neurology Disorder: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.7 Rare Disease

8.7.1 Overview

8.7.2 Rare Disease: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.8 Others

8.8.1 Overview

8.8.2 Others: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

9. NORTH AMERICA GENERIC DRUGS MARKET ANALYSIS – BY TYPE

9.1 Prescription

9.1.1 Overview

9.1.2 Prescription: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

9.2 OTC Drugs

9.2.1 Overview

9.2.2 OTC Drugs: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

10. NORTH AMERICA GENERIC DRUGS MARKET ANALYSIS – BY DISTRIBUTION CHANNEL

10.1 Hospital Pharmacies

10.1.1 Overview

10.1.2 Hospital Pharmacies: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

10.2 Retail Pharmacies

10.2.1 Overview

10.2.2 Retail Pharmacies: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

10.3 Online Pharmacies

10.3.1 Overview

10.3.2 Online Pharmacies: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

11. NORTH AMERICA GENERIC DRUGS MARKET – COUNTRY ANALYSIS

11.1 North America

11.1.1 North America Generic Drugs Market – Revenue and Forecast Analysis – by Country

11.1.1.1 North America Generic Drugs Market – Revenue and Forecast Analysis – by Country

11.1.1.2 United States: North America Generic Drugs Market – Revenue and

Forecast, 2021–2031 (US\$ Billion)

11.1.1.2.1 United States: North America Generic Drugs Market Share – by Molecule Type

11.1.1.2.2 United States: North America Generic Drugs Market Share – by Indication

11.1.1.2.3 United States: North America Generic Drugs Market Share – by Type

11.1.1.2.4 United States: North America Generic Drugs Market Share – by Distribution Channel

11.1.1.3 Canada: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

11.1.1.3.1 Canada: North America Generic Drugs Market Share – by Molecule Type

11.1.1.3.2 Canada: North America Generic Drugs Market Share – by Indication

11.1.1.3.3 Canada: North America Generic Drugs Market Share – by Type

11.1.1.3.4 Canada: North America Generic Drugs Market Share – by Distribution Channel

11.1.1.4 Mexico: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

11.1.1.4.1 Mexico: North America Generic Drugs Market Share – by Molecule Type

11.1.1.4.2 Mexico: North America Generic Drugs Market Share – by Indication

11.1.1.4.3 Mexico: North America Generic Drugs Market Share – by Type

11.1.1.4.4 Mexico: North America Generic Drugs Market Share – by Distribution Channel

12. INDUSTRY LANDSCAPE

12.1 Overview

12.2 Expansion

12.3 New Product Development/ Launch/ Approvals

12.4 Merger and Acquisition/Partnership

12.5 Other Business Strategies

13. COMPANY PROFILES

13.1 Teva Pharmaceutical Industries Ltd

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

- 13.1.6 Key Developments
- 13.2 Viatris Inc
 - 13.2.1 Key Facts
 - 13.2.2 Business Description
 - 13.2.3 Products and Services
 - 13.2.4 Financial Overview
 - 13.2.5 SWOT Analysis
 - 13.2.6 Key Developments
- 13.3 Dr. Reddy's Laboratories Ltd
 - 13.3.1 Key Facts
 - 13.3.2 Business Description
 - 13.3.3 Products and Services
 - 13.3.4 Financial Overview
 - 13.3.5 SWOT Analysis
 - 13.3.6 Key Developments
- 13.4 Novartis AG
 - 13.4.1 Key Facts
 - 13.4.2 Business Description
 - 13.4.3 Products and Services
 - 13.4.4 Financial Overview
 - 13.4.5 SWOT Analysis
 - 13.4.6 Key Developments
- 13.5 Sun Pharmaceutical Industries Ltd
 - 13.5.1 Key Facts
 - 13.5.2 Business Description
 - 13.5.3 Products and Services
 - 13.5.4 Financial Overview
 - 13.5.5 SWOT Analysis
 - 13.5.6 Key Developments
- 13.6 AbbVie Inc
 - 13.6.1 Key Facts
 - 13.6.2 Business Description
 - 13.6.3 Products and Services
 - 13.6.4 Financial Overview
 - 13.6.5 SWOT Analysis
 - 13.6.6 Key Developments
- 13.7 AstraZeneca Plc
 - 13.7.1 Key Facts
 - 13.7.2 Business Description

- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 Sanofi SA
 - 13.8.1 Key Facts
 - 13.8.2 Business Description
 - 13.8.3 Products and Services
 - 13.8.4 Financial Overview
 - 13.8.5 SWOT Analysis
 - 13.8.6 Key Developments
- 13.9 Aurobindo Pharma Ltd
 - 13.9.1 Key Facts
 - 13.9.2 Business Description
 - 13.9.3 Products and Services
 - 13.9.4 Financial Overview
 - 13.9.5 SWOT Analysis
 - 13.9.6 Key Developments
- 13.10 Glenmark Pharmaceuticals Ltd
 - 13.10.1 Key Facts
 - 13.10.2 Business Description
 - 13.10.3 Products and Services
 - 13.10.4 Financial Overview
 - 13.10.5 SWOT Analysis
 - 13.10.6 Key Developments

14. APPENDIX

- 14.1 Glossary of Terms
- 14.2 About The Insight Partners

List Of Tables

LIST OF TABLES

Table 1. North America Generic Drugs Market Segmentation

Table 2. North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Table 3. North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Molecule Type

Table 4. North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Indication

Table 5. North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Type

Table 6. North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Distribution Channel

Table 7. North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Country

Table 8. United States: North America Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type

Table 9. United States: North America Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication

Table 10. United States: North America Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Type

Table 11. United States: North America Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel

Table 12. Canada: North America Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type

Table 13. Canada: North America Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication

Table 14. Canada: North America Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Type

Table 15. Canada: North America Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel

Table 16. Mexico: North America Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type

Table 17. Mexico: North America Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication

Table 18. Mexico: North America Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Type

Table 19. Mexico: North America Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel

Table 20. Glossary of Terms, Pharmaceutical Market

List Of Figures

LIST OF FIGURES

Figure 1. North America Generic Drugs Market Segmentation – Country

Figure 2. PEST Analysis

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. North America Generic Drugs Market Revenue (US\$ Billion), 2021–2031

Figure 5. North America Generic Drugs Market Share (%) – by Molecule Type (2024 and 2031)

Figure 6. Antidepressants: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 7. Antihistamines: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 8. Analgesics: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 9. Antibiotics: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 10. Antivirals: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 11. Diuretics: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 12. Others: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 13. North America Generic Drugs Market Share (%) – by Indication (2024 and 2031)

Figure 14. Metabolic Diseases: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 15. Cancer: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 16. Immunology: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 17. Respiratory Disorder: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 18. Cardiovascular Disorder: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 19. Neurology Disorder: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 20. Rare Disease: North America Generic Drugs Market – Revenue and

Forecast, 2021–2031 (US\$ Billion)

Figure 21. Others: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 22. North America Generic Drugs Market Share (%) – by Type (2024 and 2031)

Figure 23. Prescription: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 24. OTC Drugs: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 25. North America Generic Drugs Market Share (%) – by Distribution Channel (2024 and 2031)

Figure 26. Hospital Pharmacies: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 27. Retail Pharmacies: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 28. Online Pharmacies: North America Generic Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 29. North America Generic Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)

Figure 30. United States: North America Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US\$ Billion)

Figure 31. Canada: North America Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US\$ Billion)

Figure 32. Mexico: North America Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US\$ Billion)

I would like to order

Product name: North America Generic Drugs Market Size and Forecast (2021 - 2031) Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Molecule Type (Antidepressants, Antihistamines, Analgesics, Antibiotics, Antivirals, Diuretics, and Other Molecule Types), Indication (Metabolic Diseases, Cancer, Immunology, Respiratory Disorder, Cardiovascular Disorder, Neurology Disorder, Rare Diseases, and Other Indications), Type (Prescription and OTC Drugs), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Product link: <https://marketpublishers.com/r/N1E3DEF36A00EN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N1E3DEF36A00EN.html>